1959;184(Suppl
And the availability of oral medication licensed for weight loss, like orforglipron, could help ease shortages
Patients with obesity or overweight and metabolic complicationssuch as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular diseaserepresent appropriate candidates for tirzepatide's weight management indication
The Phase 2 trial protocol specified that missed doses should not be doubled on the next injection day
This article can't resolve which document governs
The benefits of GLP 1RAs in improving body weight, metabolic health, and cardiovascular risk have been well - supported by a large number of high - quality randomized controlled trials and large - scale outcome studies [7, 9, 49, 50]